Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 1e51dfa0b5134d108b8f777e67eb63f5277e14bf
First added on: Feb 08, 2025